CERS

Cerus Corp

Add to Watchlist

Advanced Chart

1.240

-0.05(-3.876%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.310

Open

1.280

VWAP

1.26

Vol

1.14M

Mkt Cap

237.71M

Low

1.220

Amount

1.43M

EV/EBITDA(TTM)

Total Shares

184.89M

254.90M

EV/OCF(TTM)

44.68

P/S(TTM)

1.19

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

52.43M

+21.25%

-0.030

-25%

54.20M

+6.67%

-0.005

-50%

50.10M

+8.87%

-0.020

-0%

Estimates Revision

The market is revising Upward the revenue expectations for Cerus Corporation (CERS) for FY2025, with the revenue forecasts being adjusted by 1.69% over the past three months. During the same period, the stock price has changed by -4.62%.

Revenue Estimates for FY2025

Revise Upward

+1.69%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-15%

In Past 3 Month

Stock Price

Go Down

-4.62%

In Past 3 Month

4 Analyst Rating

276.61% Upside

Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.67 USD with a low forecast of 4.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

276.61% Upside

Current: 1.240

Low

4.00

Averages

4.67

High

5.00

276.61% Upside

Current: 1.240

Low

4.00

Averages

4.67

High

5.00

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-02-21

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-02-21

Reiterates

Buy

Reason

Stifel

Mathew Blackman

Strong Buy

Maintains

$6 → $3

2024-10-17

Reason

Stifel

Mathew Blackman

Price Target

$6 → $3

2024-10-17

Maintains

Strong Buy

Reason

Stifel analyst Mathew Blackman lowered the firm's price target on Cerus to $3 from $6 and keeps a Buy rating on the shares after the company announced that the EU INTERCEPT Red Blood Cells review had concluded without an approval, citing the need for additional data. While stating that "there's no denying this is a disappointing update," and that the firm would expect the shares to trade-off on this news, the analyst tells investors that at the current valuation, the firm believes the roughly $1.00 per share in value it ascribed for the EU RBC program is "already discounted in the price." While removing $1.00 per share value for the US RBC program, reflecting an increased risk profile, the firm is also contemplating a lower base business multiple, leading to its revised target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cerus Corp (CERS.O) is -18.60, compared to its 5-year average forward P/E of -18.47. For a more detailed relative valuation and DCF analysis to assess Cerus Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.47

Current PE

-18.60

Overvalued PE

-13.02

Undervalued PE

-23.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.73

Current EV/EBITDA

29.20

Overvalued EV/EBITDA

52.97

Undervalued EV/EBITDA

-72.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.41

Current PS

1.14

Overvalued PS

7.47

Undervalued PS

1.36

Financials

Annual

Quarterly

FY2025Q2

YoY :

+3.81%

52.45M

Total Revenue

FY2025Q2

YoY :

+189.55%

-11.11M

Operating Profit

FY2025Q2

YoY :

-1.04%

-5.72M

Net Income after Tax

FY2025Q2

YoY :

-0.00%

-0.03

EPS - Diluted

FY2025Q2

YoY :

-919.33%

-2.93M

Free Cash Flow

FY2025Q2

YoY :

-7.28%

55.25

Gross Profit Margin - %

FY2025Q2

YoY :

-112.06%

1.68

FCF Margin - %

FY2025Q2

YoY :

-4.64%

-10.90

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 1840.87% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.3M

USD

6-9

Months

64.2K

USD

0-12

Months

178.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

2.9K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.1M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

437.9K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 1840.87% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

1.3M

USD

6-9

Months

64.2K

USD

0-12

Months

178.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

2.9K

USD

Months

0-12

0.0

USD

Months

CERS News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

16:14:01

Cerus reports Q2 EPS (3c), consensus (2c)

2025-07-21 (ET)

2025-07-21

09:30:48

Cerus announces additional DoD award to advance hemorrhage care

2025-05-28 (ET)

2025-05-28

09:16:16

Cerus gets multiple in-country approvals for INT200 illumination device

News

8.5

07-21Newsfilter

Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury

4.0

07-03NASDAQ.COM

Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 7/3/2025

9.0

07-02Newsfilter

Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update

People Also Watch

CIX

CompX International Inc

Nabors Energy Transition Corp II

Civista Bancshares Inc

Huntington Bancshares Inc

Neumora Therapeutics Inc

Trevi Therapeutics Inc

FAQ

What is Cerus Corp (CERS) stock price today?

The current price of CERS is 1.24 USD — it has decreased -3.88 % in the last trading day.

CERS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CERS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Cerus Corp (CERS) stock price today?

What is Cerus Corp (CERS)'s business?

What is the price predicton of CERS Stock?

What is Cerus Corp (CERS)'s revenue for the last quarter?

What is Cerus Corp (CERS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Cerus Corp (CERS)'s fundamentals?

How many employees does Cerus Corp (CERS). have?

What is Cerus Corp (CERS) market cap?